Curocell, a company specializing in CAR-T therapy, announced the appointment of Lee Seung-won as managing director to spearhead the domestic commercialization of its next-generation CAR-T treatment, CRC01.
Lee brings over 20 years of expertise in brand marketing, with a strong focus on hematologic cancers and CAR-T (Chimeric Antigen Receptor-T) therapeutics.
According to Curocell, Lee served as a product manager at Novartis Korea for the hematologic cancer drug Jakavi (ruxolitinib), cell therapy network manager for the Cell & Gene team, and head of sales force training, contributing to the domestic launch and marketing of cardiovascular, diabetes, and heart failure products.
Lee started his career as a general hospital sales representative at Hanmi Pharmaceutical. He graduated from Kyungpook National University with a bachelor's degree in economics and a double major in business administration.
Curocell aims to accelerate the approval process for Anbal-cel by utilizing the tailored review under the Advanced Biopharmaceutical Expedited Processing System within the Global Innovative Product Test (GIFT), as well as the parallel approval, evaluation, and negotiation pilot project.
“The appointment of Lee Seung-won is expected to accelerate the commercialization of Anbal-cel further,” a Curocell official said. “He will play a significant role in laying the foundation for global expansion beyond the domestic market”.